H.C. Wainwright reiterates Opko Health stock rating on Labcorp deal

H.C. Wainwright has maintained its Buy rating and set a $3.00 price target for Opko Health (NASDAQ: OPK) following the announcement that Labcorp (NASDAQ: LAB) will acquire a portion of BioReference Health, a subsidiary of Opko Health. The acquisition price is $722 million in cash at closing, with the possibility of an additional $150 million in an earnout based on the 4Kscore Test's revenue.

Labcorp anticipates the business revenue to reach around $250 million in the first year following the acquisition, which is expected to close in the first half of 2027.

This transaction is the third between Labcorp and BioReference assets, coming after $192.5 million and $237.5 million deals in March 2025 and March 2024, respectively. Opko Health reported solid financial results for Q2 2026, with revenue increasing by 4.3% to $163.6 million, surpassing the company's forecast of $130.0 million. Revenue from pharmaceuticals rose 5.4% year-over-year to $42.9 million, mainly driven by growth in Spanish and Mexican markets and favorable currency exchange rates.

Opko Health's loss per share was smaller than expected at $0.01, beating analysts' predictions of a $0.08 loss. These positive developments have led H.C. Wainwright to reiterate its Buy rating for Opko Health, reflecting a promising outlook for the company.